Results 251 to 260 of about 5,591,095 (382)

Variable stars in Variable Star Field 193.

The Astronomical Journal, 1957
openaire   +3 more sources

Simultaneous inhibition of TRIM24 and TRIM28 sensitises prostate cancer cells to antiandrogen therapy, decreasing VEGF signalling and angiogenesis

Molecular Oncology, EarlyView.
TRIM24 and TRIM28 are androgen receptor (AR) coregulators which exhibit increased expression with cancer progression. Both TRIM24 and TRIM28 combine to influence the response of castrate‐resistant prostate cancer (CRPC) cells to AR inhibitors by mediating AR signalling, regulation of MYC and upregulating VEGF to promote angiogenesis. Castrate‐resistant
Damien A. Leach, Nilesh Chatterjee, Kellie Spahr, Gilberto Serrano de Almeida, Anabel Varela‐Carver, Taimur T. Shah, Mathias Winkler, Hashim U. Ahmed, Charlotte L. Bevan   +8 more
wiley   +1 more source

New Variable Star (R Libræ), by Norman Pogson, Esq [PDF]

Norman Pogson
openalex   +1 more source

EMT‐associated bias in the Parsortix® system observed with pancreatic cancer cell lines

Molecular Oncology, EarlyView.
The Parsortix® system was tested for CTC enrichment using pancreatic cancer cell lines with different EMT phenotypes. Spike‐in experiments showed lower recovery of mesenchymal‐like cells. This was confirmed with an EMT‐inducible breast cancer cell line.
Nele Vandenbussche, Renske Imschoot, Béatrice Lintermans, Lode Denolf, Joachim Taminau, Charlotte Fieuws, Geert Berx, Kris Gevaert, Kathleen B. M. Claes   +8 more
wiley   +1 more source

Tumor clusters with divergent inflammation and human retroelement expression determine the clinical outcome of patients with serous ovarian cancer

Molecular Oncology, EarlyView.
Analysis of treatment‐naïve high‐grade serous ovarian carcinoma (HGSOC) and control tissues for ERVs, LINE‐1 (L1), inflammation, and immune checkpoints identified five clusters with diverse patient recurrence‐free survivals. An inflammation score was calculated and correlated with retroelement expression, where one novel cluster (Triple‐I) with high ...
Laura Glossner, Markus Eckstein, Christoph Mark, Matthias W. Beckmann, Arndt Hartmann, Pamela L. Strissel, Reiner Strick   +6 more
wiley   +1 more source

Disease activity and treatment response in early rheumatoid arthritis: an exploratory metabolomic profiling in the NORD-STAR cohort. [PDF]

Arthritis Res Ther
Fatima T, Zhang Y, Vasileiadis GK, Rawshani A, van Vollenhoven R, Lampa J, Gudbjornsson B, Haavardsholm EA, Nordström D, Gröndal G, Hørslev-Petersen K, Lend K, Heiberg MS, Hetland ML, Nurmohamed M, Østergaard M, Uhlig T, Sokka-Isler T, Rudin A, Maglio C.   +19 more
europepmc   +1 more source

On the Variable Star R Vulpeculae [PDF]

G. Knott
openalex   +1 more source

On the Variable Star U. Geminorum [PDF]

, 1878
G. Knott
openalex   +1 more source

EGFR‐STAT3 activation provides a therapeutic rationale for targeting aggressive ETV1‐positive prostate cancer

Molecular Oncology, EarlyView.
Cotargeting EGFR and STAT3 with Erlotinib and TTI‐101 impairs both 2D and 3D growth of ETV1‐overexpressing prostate cancer cells by disrupting a self‐sustaining ETV1–EGFR positive feedback loop that promotes EGFR and STAT3 expression and phosphorylation (activation).
Elsa Gomes Paiva, Bernardo Orr, Ana Azeredo, Andreia Brandão, Manuel R. Teixeira, Paula Paulo   +5 more
wiley   +1 more source

School-based enhanced hearing screening and specialty telehealth follow-up for hearing loss among children in rural Alaska: study protocol for a hybrid effectiveness-implementation stepped wedge, cluster-randomized controlled trial (North STAR trial). [PDF]

Trials
Robler SK, Bettger JP, Turner E, Platt A, Arthur D, Hofstetter P, Lane H, Srinivasan T, Deshpande S, Hirschfeld M, Emmett SD.   +10 more
europepmc   +1 more source